News
-
-
PRESS RELEASE
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting -
-
PRESS RELEASE
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial -
-
PRESS RELEASE
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise -
-
-
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) will conduct an investor webcast on April 1, 2024, at 8:30 a.m. EST to review fourth-quarter financials and corporate updates. Company plans to file its Earnings Report on Form 10-K for year ended December 31, 2023